• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Added therapeutic benefit regarding ESMO-MCBS and the French health technology assessment of drugs granted early access program.

作者信息

Pham F Y-V, Jacquet E, Monard A, Brunel L, Blay J-Y, Albin N

机构信息

Oncology Hematology and Cell Therapy Department, French National Agency for Safety of Medicines and Health Products, Saint-Denis, France; Department of Pharmacy, Centre hospitalo-universitaire Hôpital Henri Mondor Assistance Publique des Hôpitaux de Paris, Créteil, France.

Department of Oncohematology, Centre Hospitalier Universitaire Grenoble-Alpes, Grenoble, France.

出版信息

Ann Oncol. 2022 May;33(5):561-563. doi: 10.1016/j.annonc.2022.02.002. Epub 2022 Feb 14.

DOI:10.1016/j.annonc.2022.02.002
PMID:35176459
Abstract
摘要

相似文献

1
Added therapeutic benefit regarding ESMO-MCBS and the French health technology assessment of drugs granted early access program.在欧洲肿瘤内科学会-综合获益量表（ESMO-MCBS）以及法国药品早期准入计划的卫生技术评估方面增加了治疗获益。
Ann Oncol. 2022 May;33(5):561-563. doi: 10.1016/j.annonc.2022.02.002. Epub 2022 Feb 14.
2
Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019.2009 年至 2019 年期间，通过法国临时用药授权计划获得早期准入的固体肿瘤药物的生存、成本和附加治疗效益。
Int J Cancer. 2022 Oct 15;151(8):1345-1354. doi: 10.1002/ijc.34129. Epub 2022 Jul 7.
3
Appraisal of cancer drugs: a comparison of the French health technology assessment with value frameworks of two oncology societies.癌症药物评估：法国卫生技术评估与两个肿瘤学会价值框架的比较。
Expert Rev Pharmacoecon Outcomes Res. 2020 Aug;20(4):405-409. doi: 10.1080/14737167.2019.1635458. Epub 2019 Jun 26.
4
Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit.欧洲药品管理局（EMA）批准的用于实体瘤的五年全身癌症治疗——两种有意义临床获益阈值的比较
Eur J Cancer. 2017 Sep;82:66-71. doi: 10.1016/j.ejca.2017.05.029. Epub 2017 Jul 10.
5
The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.新型肿瘤药物的ESMO临床获益量表幅度：与以色列三年报销决策的对应关系。
Expert Rev Pharmacoecon Outcomes Res. 2018 Feb;18(1):119-122. doi: 10.1080/14737167.2017.1343146. Epub 2017 Jun 21.
6
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.研究设计、实施和数据分析中的偏倚会扭曲对临床获益的评估和 ESMO-MCBS 评分。
ESMO Open. 2021 Jun;6(3):100117. doi: 10.1016/j.esmoop.2021.100117. Epub 2021 Apr 20.
7
Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time.随着时间的推移，使用欧洲医学肿瘤学会临床获益程度量表评估欧洲药品管理局批准的癌症药物的获益情况。
Eur J Cancer. 2021 Jun;150:203-210. doi: 10.1016/j.ejca.2021.03.044. Epub 2021 Apr 29.
8
Clinical benefit of cancer drugs approved in Switzerland 2010-2019.2010-2019 年在瑞士获批的癌症药物的临床获益。
PLoS One. 2022 Jun 10;17(6):e0268545. doi: 10.1371/journal.pone.0268545. eCollection 2022.
9
Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'.十二年欧洲抗癌药物审批-对“临床获益幅度”的系统调查
ESMO Open. 2021 Jun;6(3):100166. doi: 10.1016/j.esmoop.2021.100166. Epub 2021 Jun 1.
10
Examining the association between oncology drug clinical benefit and the time to public reimbursement.考察肿瘤药物临床获益与公共报销时间之间的关联。
Cancer Med. 2022 Jan;11(2):380-391. doi: 10.1002/cam4.4455. Epub 2021 Dec 1.

引用本文的文献

1
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric Cancer in a Real-World Setting: A Nationwide Cohort Study.曲妥珠单抗德鲁替康在真实世界中用于人表皮生长因子受体2阳性转移性胃癌的研究：一项全国性队列研究
Clin Transl Gastroenterol. 2024 Dec 1;15(12):e00773. doi: 10.14309/ctg.0000000000000773.
2
Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments.肿瘤学试验设计的意义以及疗效-安全性数据的不确定性对卫生技术评估的影响。
Curr Oncol. 2022 Aug 16;29(8):5774-5791. doi: 10.3390/curroncol29080455.
3
Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019.
2009 年至 2019 年期间，通过法国临时用药授权计划获得早期准入的固体肿瘤药物的生存、成本和附加治疗效益。
Int J Cancer. 2022 Oct 15;151(8):1345-1354. doi: 10.1002/ijc.34129. Epub 2022 Jul 7.
4
Is It Time to Commit to a Process to Re-Evaluate Oncology Drugs? A Descriptive Analysis of Systemic Therapies for Solid Tumour Indications Reviewed in Canada from 2017 to 2021.是否到了承诺重新评估肿瘤药物的过程的时候了？对 2017 年至 2021 年在加拿大审查的用于实体瘤适应证的系统疗法进行描述性分析。
Curr Oncol. 2022 Mar 10;29(3):1919-1931. doi: 10.3390/curroncol29030156.